Highlights
- The DAPT-SHOCK-AMI trial demonstrated superior platelet inhibition with intravenous cangrelor compared to crushed ticagrelor at the end of primary PCI in AMI complicated by cardiogenic shock.
- Despite more consistent platelet inhibition, cangrelor did not meet non-inferiority for the 30-day composite clinical endpoint of death, MI, or ischemic stroke compared with crushed ticagrelor.
- Bleeding risks were comparable between cangrelor and crushed ticagrelor, underscoring the safety of cangrelor in this critically ill population.
- These findings inform the optimization of antiplatelet strategies in AMI-CS and support further investigation of intravenous P2Y12 inhibition in this setting.
Background
Specialty calculators
For clinical reference; use professional judgment.
